Your browser doesn't support javascript.
loading
DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.
Majrashi, Taghreed A; Sabt, Ahmed; Almahli, Hadia; El Hassab, Mahmoud A; Noamaan, Mahmoud A; Elkaeed, Eslam B; Hamissa, Mohamed Farouk; Maslamani, Abdalkareem Nael; Shaldam, Moataz A; Eldehna, Wagdy M.
Afiliação
  • Majrashi TA; Department of Pharmacognosy, College of Pharmacy, King Khalid University, Asir, Saudi Arabia.
  • Sabt A; Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo, Egypt.
  • Almahli H; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
  • El Hassab MA; Faculty of Pharmacy, Department of Medicinal Chemistry, King Salman International University (KSIU), South Sinai, Egypt.
  • Noamaan MA; Faculty of Science, Mathematics Department, Cairo University, Giza, Egypt.
  • Elkaeed EB; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah, Riyadh, Saudi Arabia.
  • Hamissa MF; Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Giza, Egypt.
  • Maslamani AN; Institute of Organic Chemistry and Biochemistry, Academy of Sciences, Prague, Czech Republic.
  • Shaldam MA; Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Eldehna WM; Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kafrelsheikh University, Kafrelsheikh, Egypt.
PLoS One ; 19(3): e0300035, 2024.
Article em En | MEDLINE | ID: mdl-38457483
ABSTRACT
The development of effective drugs targeting the K-Ras oncogene product is a significant focus in anticancer drug development. Despite the lack of successful Ras signaling inhibitors, recent research has identified PDEδ, a KRAS transporter, as a potential target for inhibiting the oncogenic KRAS signaling pathway. This study aims to investigate the interactions between eight K-Ras inhibitors (deltarazine, deltaflexin 1 and 2, and its analogues) and PDEδ to understand their binding modes. The research will utilize computational techniques such as density functional theory (DFT) and molecular electrostatic surface potential (MESP), molecular docking, binding site analyses, molecular dynamic (MD) simulations, electronic structure computations, and predictions of the binding free energy. Molecular dynamic simulations (MD) will be used to predict the binding conformations and pharmacophoric features in the active site of PDEδ for the examined structures. The binding free energies determined using the MMPB(GB)SA method will be compared with the observed potency values of the tested compounds. This computational approach aims to enhance understanding of the PDEδ selective mechanism, which could contribute to the development of novel selective inhibitors for K-Ras signaling.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Simulação de Dinâmica Molecular Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Simulação de Dinâmica Molecular Idioma: En Ano de publicação: 2024 Tipo de documento: Article